For a 56-year-old adult requiring a 150 mg monthly dose, is haloperidol decanoate available as a 150 mg/mL preparation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Haloperidol Decanoate 150 mg/mL Concentration Availability

Yes, haloperidol decanoate is available as a 150 mg/mL concentration, and this formulation can be used to deliver a 150 mg monthly dose with a single 1 mL injection 1.

Available Formulations

The FDA-approved haloperidol decanoate product is supplied in a concentration that allows for 150 mg to be administered. Based on the drug labeling, the maximum volume per injection site should not exceed 3 mL, and a 21-gauge needle is recommended for deep intramuscular injection 1.

Dosing Context for 150 mg Monthly

For a 56-year-old adult requiring 150 mg monthly:

  • This dose falls within the typical maintenance range described in the FDA labeling, which states that maintenance dosing is usually 10-15 times the previous daily oral haloperidol dose 1

  • The 150 mg dose is clinically appropriate for patients previously stabilized on moderate oral haloperidol doses (approximately 10-15 mg/day oral haloperidol equivalent) 1

  • Research confirms that 150 mg formulations have been successfully used in clinical practice, with studies documenting good tolerability and efficacy at this dose level 2, 3

Administration Considerations

The injection should be administered as a deep intramuscular injection using a 21-gauge needle 1. One case report highlights that needle length matters—a 2-inch needle may be necessary in patients with significant adipose tissue to ensure proper intramuscular delivery rather than subcutaneous deposition 4.

Dosing interval is typically monthly (every 4 weeks), though this can be adjusted based on individual patient response 1. Clinical supervision is required during initial dose adjustment to minimize risk of overdosage or symptom recurrence 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.